In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eleanor Malone

London, UK
Eleanor has been editor of Scrip Intelligence since 2014. She has more than 15 years’ experience writing specialist news and analysis for and about the biopharma industry. She holds an MA in modern languages from the University of Edinburgh. Based in London, she appears regularly on TV and radio and conference panels to discuss matters related to the industry.
Set Alert for Articles By Eleanor Malone

Latest From Eleanor Malone

Editor's Note: Join Our Survey To Shape Scrip's Future

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the format of the content or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

 

BioPharmaceutical

What Does 2020 Hold For Biopharma?

Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.

BioPharmaceutical Business Strategies

Scrip Asks… What Does 2020 Hold For Biopharma? Part 4: The Patient

From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.

Personalized Medicine Artificial Intelligence

Scrip Asks…What Does 2020 Hold For Biopharma? Part 3: Policy And Regulation

The US election will intensify  the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.

Policy Regulation

Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business And Investment

Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.

Commercial Business Strategies

Scrip Asks…What Does 2020 Hold For Biopharma? Part 1: Therapeutic Advances

Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.

 

Innovation Market Intelligence
See All
UsernamePublicRestriction

Register